Foghorn Therapeutics Inc

+0.16 (+1.30%)
Earnings Announcements

Foghorn Therapeutics Reports Q4 Loss Per Share $3.12

Published: 12/04/2020 13:08 GMT
Foghorn Therapeutics Inc (FHTX) - Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update.
Q3 Loss per Share $3.12.
Q3 Earnings per Share Estimate $-1.72 -- Refinitiv Ibes Data (analyst estimates).
Cash and Cash Equivalents As of September 30, 2020 Were $74.6 Million.
Revenue is expected to be $0.17 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0.17 Million
Next Quarter EPS Guidance is expected to be -$0.61

More details on our Analysts Page.